
Opinion|Videos|January 27, 2025
Shared Decision-Making for IgAN Treatment
Key Takeaways
- Biomarkers, including genetic mutations and protein expressions, are vital for predicting disease progression and treatment response.
- Advanced diagnostic techniques are essential for identifying molecular and cellular indicators that inform patient prognosis.
Panelists discuss how shared decision-making is essential when considering emerging treatments vs established therapies, emphasizing the importance of aligning treatment choices with patient preferences and values to enhance adherence and optimize outcomes in IgA nephropathy care.
Advertisement
Episodes in this series

- What role does shared decision-making play when considering emerging treatments vs established therapies?
Advertisement
Advertisement
Advertisement
Trending on HCPLive
1
Single Dose of CIDEB siRNA Normalizes Liver Fat in MASLD Through 36 Weeks
2
Lp(a)HORIZON, Oral PCSK9s, and 2027 Lipid Trials, with Kausik Ray, MD, MBChB, MPhil
3
COMP360 Psilocybin NDA Submitted to FDA for Treatment-Resistant Depression
4
What’s New in the 2027 GOLD Report for COPD
5

